Brokerages expect Intellia Therapeutics Inc (NASDAQ:NTLA) to announce ($0.57) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Intellia Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.50). Intellia Therapeutics reported earnings of ($0.45) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 26.7%. The business is expected to issue its next earnings results on Tuesday, August 7th.
On average, analysts expect that Intellia Therapeutics will report full year earnings of ($2.00) per share for the current financial year, with EPS estimates ranging from ($2.33) to ($1.65). For the next year, analysts anticipate that the firm will post earnings of ($2.71) per share, with EPS estimates ranging from ($3.09) to ($2.11). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Tuesday, May 1st. The company reported ($0.51) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.07. The business had revenue of $7.47 million during the quarter, compared to analyst estimates of $6.14 million. Intellia Therapeutics had a negative return on equity of 31.80% and a negative net margin of 278.64%.
Several analysts have recently weighed in on the company. BidaskClub upgraded Intellia Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 13th. JMP Securities initiated coverage on Intellia Therapeutics in a report on Thursday, March 8th. They set an “outperform” rating for the company. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Intellia Therapeutics in a report on Thursday, March 15th. Leerink Swann reaffirmed an “outperform” rating on shares of Intellia Therapeutics in a report on Wednesday, March 14th. Finally, ValuEngine raised Intellia Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $34.83.
Shares of Intellia Therapeutics traded up $1.78, hitting $31.44, during trading on Friday, MarketBeat reports. The stock had a trading volume of 854,214 shares, compared to its average volume of 1,064,537. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of -16.60 and a beta of 3.20. Intellia Therapeutics has a fifty-two week low of $14.45 and a fifty-two week high of $35.99.
In related news, insider John M. Leonard sold 8,400 shares of the company’s stock in a transaction on Monday, May 14th. The stock was sold at an average price of $24.00, for a total transaction of $201,600.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jean Francois Formela sold 6,686 shares of the company’s stock in a transaction on Wednesday, May 16th. The shares were sold at an average price of $25.04, for a total value of $167,417.44. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,772 shares of company stock valued at $555,958. 12.80% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the stock. Royal Bank of Canada raised its position in Intellia Therapeutics by 521.7% during the first quarter. Royal Bank of Canada now owns 30,320 shares of the company’s stock valued at $640,000 after buying an additional 25,443 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Intellia Therapeutics during the first quarter valued at $252,000. Barclays PLC raised its position in Intellia Therapeutics by 112.8% during the first quarter. Barclays PLC now owns 19,778 shares of the company’s stock valued at $416,000 after buying an additional 10,483 shares during the period. UBS Group AG raised its position in Intellia Therapeutics by 131.6% during the first quarter. UBS Group AG now owns 191,616 shares of the company’s stock valued at $4,041,000 after buying an additional 108,878 shares during the period. Finally, Platinum Investment Management Ltd. acquired a new position in Intellia Therapeutics during the first quarter valued at $1,159,000. 60.74% of the stock is currently owned by hedge funds and other institutional investors.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.